Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication

NCT01157871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Arterial Occlusive Disease

Interventions

DRUG: XRP0038 (NV1FGF)
DRUG: placebo

Sponsor

Sanofi